The arrival of Wegovy two years ago caused turmoil in health services around the world ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting approval to Novo Nordisk India for its proposed update to ...

YOU may be keen to shed pounds from your waistline with fat jabs, but forking out the monthly bill is less appealing – ...

Amy Schumer made the bombshell announcement that she is divorcing husband Chris Fischer amid reports of turmoil in their ...

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy. Group revenues came ...